Blood angiopoietin-2 predicts liver angiogenesis and fibrosis in hepatitis C patients

[1]  N. Sakamoto,et al.  High serum angiopoietin‐2 level predicts non‐regression of liver stiffness measurement‐based liver fibrosis stage after direct‐acting antiviral therapy for hepatitis C , 2020, Hepatology research : the official journal of the Japan Society of Hepatology.

[2]  C. Vanhove,et al.  Angiopoietin‐2 Promotes Pathological Angiogenesis and Is a Therapeutic Target in Murine Nonalcoholic Fatty Liver Disease , 2019, Hepatology.

[3]  R. Thadhani,et al.  Serum Angiopoietin‐2 Predicts Mortality and Kidney Outcomes in Decompensated Cirrhosis , 2019, Hepatology.

[4]  G. Giannelli,et al.  Liver Angiopoietin‐2 Is a Key Predictor of D e N ovo or Recurrent Hepatocellular Cancer After Hepatitis C Virus Direct‐Acting Antivirals , 2018, Hepatology.

[5]  Hui Zhao,et al.  Mechanotransduction-modulated fibrotic microniches reveal the contribution of angiogenesis in liver fibrosis. , 2017, Nature materials.

[6]  Shaker A. Mousa,et al.  The Role of Angiogenesis in Cancer Treatment , 2017, Biomedicines.

[7]  Xiao Liang,et al.  Sorafenib: A potential therapeutic drug for hepatic fibrosis and its outcomes. , 2017, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[8]  Richard Moreau,et al.  Liver sinusoidal endothelial cells: Physiology and role in liver diseases. , 2017, Journal of hepatology.

[9]  M. Borque,et al.  Angiopoietin-2/angiopoietin-1 as non-invasive biomarker of cirrhosis in chronic hepatitis C , 2016, World journal of gastroenterology.

[10]  D. Siemann,et al.  Targeting the Angiopoietin-2/Tie-2 axis in conjunction with VEGF signal interference. , 2016, Cancer letters.

[11]  K. Alitalo,et al.  Opposing actions of angiopoietin-2 on Tie2 signaling and FOXO1 activation. , 2016, The Journal of clinical investigation.

[12]  V. Shah,et al.  Sinusoidal communication in liver fibrosis and regeneration. , 2016, Journal of hepatology.

[13]  K. Alitalo,et al.  Tie1 controls angiopoietin function in vascular remodeling and inflammation. , 2016, The Journal of clinical investigation.

[14]  L. DeLeve Liver sinusoidal endothelial cells in hepatic fibrosis , 2015, Hepatology.

[15]  G. Elpek Angiogenesis and liver fibrosis. , 2015, World journal of hepatology.

[16]  F. Rodríguez-Pascual,et al.  The profibrotic role of endothelin-1: is the door still open for the treatment of fibrotic diseases? , 2014, Life sciences.

[17]  H. Augustin,et al.  Angiopoietin-2: an attractive target for improved antiangiogenic tumor therapy. , 2013, Cancer research.

[18]  H. Nagai,et al.  Serum VEGF as a tumor marker in patients with HCV-related liver cirrhosis and hepatocellular carcinoma. , 2013, Anticancer research.

[19]  Jun-ji Ma,et al.  New insights into the antifibrotic effects of sorafenib on hepatic stellate cells and liver fibrosis. , 2010, Journal of hepatology.

[20]  K. Iwaisako,et al.  Hepatic stellate cells secrete angiopoietin 1 that induces angiogenesis in liver fibrosis. , 2008, Gastroenterology.

[21]  M. Borque,et al.  The potential of angiogenesis soluble markers in chronic hepatitis C , 2005, Hepatology.

[22]  D. Auclair,et al.  BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis , 2004, Cancer Research.

[23]  H. Yu,et al.  Overexpression of VEGF and Angiopoietin 2: A Key to High Vascularity of Hepatocellular Carcinoma? , 2003, Modern Pathology.

[24]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[25]  D. Rockey,et al.  Cellular localization of endothelin‐1 and increased production in liver injury in the rat: Potential for autocrine and paracrine effects on stellate cells , 1998, Hepatology.